Part of dartmouth-hitchcock
Clinical Trials
485
38 active
Approvals
0
Total approvals
Agencies
0
Regulatory bodies
Founded
1983
Active, not recruiting
17
3.5%
Completed
318
65.6%
Enrolling By Invitation
3
0.6%
Not yet recruiting
18
3.7%
Recruiting
49
10.1%
Suspended
1
0.2%
Terminated
54
11.1%
Unknown
1
0.2%
Withdrawn
24
5.0%
No approval data available
- DEA's witness list for the June 29 rescheduling hearing includes Dr. Corey Burchman, who will testify that medical marijuana provides a medical benefit to pain patients based on his clinical experience. - FDA official Dominic Chiapperino will describe the eight-factor analysis supporting the recommendation to move cannabis from Schedule I to Schedule III of the Controlled Substances Act. - Prohibitionist group SAM seeks to subpoena DEA pharmacologist Luli Akinfiresoye, who previously submitted a report linking cannabis to psychosis, depression, and cognitive impairment. - No reform supporters were invited to participate in the hearing, and the DEA judge has denied livestreaming despite acknowledging national public interest in transparency.
- Advanced machine learning algorithms enable liquid biopsies for early lung cancer detection, potentially increasing annual lives saved from 600 to 12,000 in the United States through blood-based screening. - AI-powered imaging systems match radiologists' accuracy in breast cancer detection, demonstrating potential to reduce second reader workload by 88% in UK screening processes. - Deep neural networks in pathology achieve expert-level accuracy in tumor pattern classification, processing slides in under one minute while maintaining diagnostic quality comparable to practicing pathologists.
